Title |
Understanding the mechanisms of aromatase inhibitor resistance
|
---|---|
Published in |
Breast Cancer Research, January 2012
|
DOI | 10.1186/bcr2931 |
Pubmed ID | |
Authors |
William R Miller, Alexey A Larionov |
Abstract |
ABSTRACT: Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however, resistance is a major obstacle to optimal management. Evidence from endocrine, molecular and pathological measurements in clinical material taken before and after therapy with AIs and data from clinical trials in which AIs have been given as treatment either alone or in combination with other targeted agents suggest diverse causes for resistance. These include inherent tumour insensitivity to oestrogen, ineffective inhibition of aromatase, sources of oestrogenic hormones independent of aromatase, activation of signalling by non-endocrine pathways, enhanced cell survival and selection of hormone-insensitive cellular clones during treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | <1% |
France | 1 | <1% |
Unknown | 116 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 23 | 19% |
Student > Ph. D. Student | 18 | 15% |
Student > Master | 17 | 14% |
Researcher | 15 | 13% |
Student > Postgraduate | 8 | 7% |
Other | 18 | 15% |
Unknown | 19 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 28 | 24% |
Medicine and Dentistry | 24 | 20% |
Biochemistry, Genetics and Molecular Biology | 13 | 11% |
Chemistry | 10 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 8% |
Other | 10 | 8% |
Unknown | 23 | 19% |